A systematic review of obesity prevalence and its contributing factors among individuals diagnosed with schizophrenia
-
By
-
Jianmei Long
-
Bo Yang
-
Qiong Zheng
-
April 27, 2026
-
Clinical Scorecard: A systematic review of obesity prevalence and its contributing factors among individuals diagnosed with schizophrenia
At a Glance
| Category | Detail |
|---|
| Condition | Obesity in patients with schizophrenia |
| Key Mechanisms | Influencing factors include sex, metabolic parameters, and antipsychotic medication use. |
| Target Population | Patients diagnosed with schizophrenia (SCH) |
| Care Setting | Clinical settings involving psychiatric treatment |
Key Highlights
- Obesity prevalence in SCH patients is 33.0%.
- Female sex and diabetes significantly increase obesity risk.
- Olanzapine use is associated with a high odds ratio for obesity.
- Combined antipsychotic therapy raises obesity risk.
- Obesity in SCH patients correlates with metabolic disorders.
Guideline-Based Recommendations
Diagnosis
- Screen for obesity in patients with schizophrenia regularly.
Management
- Implement targeted interventions to prevent obesity.
Monitoring & Follow-up
- Monitor metabolic parameters such as FG, TG, LDL, and HDL levels.
Risks
- Be aware of increased risk of metabolic disorders and reduced life expectancy.
Patient & Prescribing Data
Adults aged 18 years and older diagnosed with schizophrenia.
Consider the impact of antipsychotic medications on weight gain.
Clinical Best Practices
- Conduct early screening for obesity risk factors.
- Educate patients on the importance of weight management.
- Tailor antipsychotic treatment to minimize obesity risk.
References
